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Abstract
In the inflammatory demyelinating neurodegenerative disease multiple sclerosis (MS),
there is increasing interest in gray matter pathology, as neuronal loss and cortical
atrophy correlate with disability and disease progression, and MS therapeutics fail to
significantly slow or stop neurodegeneration. Microglia, the central nervous system
(CNS)-resident macrophages, are extensively involved in white matter MS pathology,
but are also implicated in gray matter pathology, similarly to in other neurodegenera-
tive diseases where there is synaptic, axonal, and neuronal degeneration. Microglia
display regional heterogeneity within the CNS, which reflects their highly plastic
nature and their ability to deliver context-dependent responses tailored to the
demands of their microenvironment. Therefore, microglial roles in the MS gray mat-
ter in part reflect and in part diverge from those in the white matter. The present
review summarizes current knowledge of microglial involvement in gray matter
changes in MS, in demyelination, synaptic damage and neurodegeneration, with evi-
dence implicating microglia in pathology, neuroprotection and repair. As our under-
standing of microglial physiology and pathophysiology increases, we describe how
we are moving toward potential therapeutic applications in MS, harnessing microglia
to protect and regenerate the CNS.
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1 | INTRODUCTION
The majority of the knowledge regarding microglial involvement in
multiple sclerosis (MS) pathology comes from studying the white mat-
ter of MS patients and animal models. However, there is evidence for
microglial regional heterogeneity within the central nervous system
(CNS),1 implying that there may be phenotypic differences between
white and gray matter microglia. In addition, some features of gray
matter pathology in MS are distinct from those typical to the white
matter,2 which might require or dictate different microglial responses.
Both detrimental and beneficial roles have been reported for microglia
in the literature, due to their highly plastic nature, allowing them to
deliver tailored context-dependent responses. This review will present
evidence supporting both damaging and beneficial microglial functions
and underscore the highly complex interplay between pathological
and restorative processes in MS gray matter. Here, we have chosen to
focus on microglia only rather than other myeloid cells. The role of
invading monocyte-derived macrophages is already well-described in
CNS health and disease,3-5 and although there is increasing interest in
non-parenchymal CNS macrophages, it is difficult to separate out
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their function as these were hitherto indistinguishable from microglia.
Thus, some roles currently attributed to microglia may be, at least in
part, executed by perivascular, meningeal, and choroid plexus macro-
phages. The development of novel tools that distinguish between
microglia and non-parenchymal CNS macrophages6 is likely to
uncover their functions in MS gray matter in the future.
1.1 | What is MS?
MS is a chronic inflammatory neurodegenerative disease of the
human CNS, of putative autoimmune aetiology, thought to be
caused by complex interplay between genetic susceptibility and
environmental risk factors.7 The main pathological hallmark of MS is
the presence of areas of demyelination, termed lesions, disseminated
in time and space throughout the white and gray matter of the brain,
spinal cord and optic nerve.8 Usually, MS initially presents as a
relapsing-remitting disease, in which bouts of demyelination mani-
fest clinically as episodes of neurological dysfunction followed by
spontaneous partial or complete recovery. Over time, the majority of
MS patients transition into the secondary progressive phase of the
disease, characterized by progressive and permanent accumulation
of neurological disability.8 Multiple disease-modifying treatments
are available for the relapsing-remitting phase and aim to reduce
inflammatory demyelinating activity, but their efficacy at preventing
disability progression remains questionable.9 MS research is ham-
pered by the heterogeneous nature of the disease, as lesion pathol-
ogy, clinical course and response to disease-modifying treatments
vary greatly between patients, and are not accurately reproduced in
preclinical models.10
1.2 | The importance of gray matter pathology
in MS
The CNS is composed of two types of tissue: the white matter and
the gray matter. The white matter is rich in neuronal axons and
derives its name from the light color of the lipid-rich myelin sheaths
surrounding the axons. In the gray matter, neuronal somata, dendrites
and synapses predominate. As MS is characterized by the inflamma-
tory destruction of myelin sheaths, it has been traditionally regarded
as a disease of the white matter, where the majority of myelinated
axons are concentrated. However, many of the axons originating from
and terminating on neuronal somata in gray matter are myelinated,
and so are also affected by demyelination in MS. Gray matter MS
pathology involves demyelination, synaptic damage and neu-
rodegeneration.2 Demyelination can be repaired to some extent by
the restoration of lost myelin sheaths around axons, termed
remyelination; on the contrary, neurodegeneration in the gray matter
appears irreversible, is prominent from the earliest stages of MS and
is the substrate of a large proportion of permanent disability experi-
enced by MS patients.11,12 Furthermore, existing disease-modifying
treatments can reduce white matter lesion load but seem rather
limited in their ability to significantly reduce or prevent gray matter
neurodegeneration.13
1.3 | Microglia are involved in MS pathology
Microglia are the only resident myeloid cells in CNS parenchyma in
homeostasis, cooperating with the CNS border-associated macro-
phages.14 They constantly survey their microenvironment through
their dynamic processes, monitoring the proper function of neurons,
axons and dendrites, and phagocytosing dying cells and cellular debris
to maintain a healthy milieu.15 In the neuroinflammatory MS environ-
ment, they can secrete proinflammatory cytokines and chemokines,
promote oxidative stress and recruit peripheral immune cells across a
compromised blood-brain barrier (BBB) into the CNS.7 They are also
paramount to the resolution of inflammation, as they phagocytose
debris from myelin and cellular destruction, thus clearing the damage
and creating an environment permissive to regeneration.16 In addition,
they secrete trophic factors for specialized adult stem cells, the oligo-
dendrocyte precursor cells (OPCs), which migrate to areas of demye-
lination, differentiate into oligodendrocytes and remyelinate denuded
axons.17 Microglial functions in MS have overwhelmingly been inves-
tigated in white matter, which has traditionally been the focus of MS
research; however, research is now showing that gray matter-specific
pathological processes in MS elicit context-dependent microglial
responses that can differ from those in white matter.
2 | MICROGLIA ARE INVOLVED IN ALL
ASPECTS OF GRAY MATTER PATHOLOGY
IN MS
In the gray matter, the complex interplay between demyelination,
inflammation and neurodegeneration remains poorly understood. In
late-stage MS, degeneration of chronically demyelinated axons and
neurons is widespread in the gray matter,18 correlating with gray matter
Significance statement
Gray matter pathology in multiple sclerosis is of great cur-
rent interest as recent advances in live brain imaging reveal
that this is present from the earliest disease stages, and,
unlike white matter pathology, is significantly correlated
with disability. Microglia, resident immune cells of the brain,
are the first line of defense, with heterogeneity of their
responses depending on whether they reside in gray or
white matter. Understanding microglial responses to gray
matter-specific cues will shed light on multiple sclerosis
pathological processes and guide therapeutic strategies
targeting the gray matter for neuroprotection—an unmet
need to avoid and treat disability.
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atrophy on magnetic resonance (MR) imaging, which is present even in
early disease.19 Demyelination can drive neurodegeneration,20,21 but
inflammation can also initiate degenerative mechanisms, including the
structural and functional compromise of synapses, occurring prior to
irreversible neuronal demise.22 Evidence from other neurodegenerative
diseases increasingly points to microglia as important effectors with
both damaging and beneficial functions.23 Gray matter microglia have
been understudied, partly as microglial responses may differ between
different disease stages, gray matter lesion pathology stages and
between heterogeneous patients with different disease courses which
cannot be easily reproduced in animal models. Here, we summarize
findings of gray matter microglia in human MS and animal models, and
speculate how much white matter microglial responses in MS and other
neurodegenerative pathologies may inform us about gray matter micro-
glial responses in MS. The absence of some evidence serves to
strengthen the case for more research into gray matter-specific MS
pathology. The following sections will explore the multifaceted micro-
glial involvement in all three major aspects of MS-associated gray mat-
ter damage: demyelination, synaptic pathology, and neurodegeneration.
2.1 | Gray matter demyelination
Gray matter demyelination had been reported already by 1962,24 but
technological limitations in MR imaging obscured the true extent of
its involvement in MS. It is now appreciated that almost all MS
patients experience gray matter demyelination including in the cortex,
hippocampus, thalamus, cerebellum, and spinal cord.25 Permanent
motor, cognitive and neuropsychiatric deficits have been proposed to
at least partly have their pathological substrate in gray matter demye-
lination with the degree of dysfunction correlating better with gray
rather than white matter demyelination.26
Functional deficits caused by demyelination may be resolved to vari-
ous degrees by remyelination. Classically, remyelination is executed by
OPCs, the adult stem cells of the CNS, but recent evidence suggests that
mature surviving oligodendrocytes also contribute to this process.27,28 In
the cortical experimental autoimmune encephalomyelitis (EAE) and
cuprizone mouse models of MS, gray matter remyelination is faster and
more efficient than in white matter,29,30 and in the human MS cortex,
ultrastructural examination suggests that seemingly non-demyelinated
(normal-appearing) gray matter may in fact be extensively remyelinated.31
Whether the apparent increased propensity of the gray matter to
remyelinate is a result of different regenerative mechanisms than in white
matter, or whether similar repair processes may have greater efficiency
due to a more permissive environment remains unknown.
2.1.1 | Microglial contribution to gray matter
demyelination
In gray matter MS lesions seen on postmortem tissue, inflammation is
less prominent than in white matter lesions, with less lymphocyte infil-
tration, complement deposition and fewer microglia/myeloid cells,18
although biopsy material suggests that these feature more promi-
nently in early disease.32 However, even in postmortem tissue in
chronic MS, inflammatory infiltrates consisting of T cells, B cells and
plasma cells aggregate in the leptomeninges near subpial cortical and
cerebellar gray matter lesions,33 and in perivascular areas in deep gray
matter,34 surrounded by parenchymal activated microglia. These
observations have led to the hypothesis that soluble mediators diffuse
from meningeal or perivascular inflammatory aggregates into the gray
matter to initiate demyelination with the help of activated microglia.
Interferon-γ and tumor necrosis factor (TNF)-α are two such candi-
dates, as they are highly expressed in the meninges and are associated
with microglial activation33; furthermore, their presence in the cortex
of rats with EAE is sufficient to initiate demyelination.29 In early-stage
white matter lesions, microglia secrete proinflammatory cytokines
that directly damage myelin sheaths and their supporting
oligodendrocytes,35 but we are unclear whether this also occurs for
gray matter microglia.
Gray matter demyelination may also occur secondary to white
matter demyelination causing local axonal damage which spreads via
anterograde or retrograde degeneration to anatomically and function-
ally connected gray matter areas.36 This distant neurodegeneration is
thought to “prime” neighboring white matter microglia, so upon sub-
sequent challenge their responses are potentiated.37 It is speculated
that this may occur similarly in gray matter areas functionally con-
nected to white matter lesions, poising microglia to quickly respond to
meningeal or perivascular inflammatory infiltrates by secreting
myelinotoxic effectors initiating demyelination.38
2.1.2 | Microglia aid robust remyelination
The myeloid cells of the innate immune system are paramount to the
healing process in response to injury in peripheral tissues such as skin
and muscle. Similarly, in MS-associated CNS injury, microglia are not
confined to a damaging role but are essential for remyelination. In the
demyelinating white matter, digestion of myelin debris transforms
microglia from a pro- to an anti-inflammatory phenotype that sup-
presses inflammation to allow regeneration.39 This has previously
been described as a switch from an M1 proinflammatory to an M2
pro-regenerative state, but this is clearly an oversimplification, as
microglia can assume multiple states resembling a continuum between
the two extremes. Therefore, researchers have attempted to use
transcriptomic analysis, markers, and function to try and define these
cells better (see below), while still recognizing that the same function,
for example, myelin phagocytosis, can be either damaging (early) or
beneficial (later) depending on timing with respect to lesion
pathology.
Microglia abound in remyelinating white matter lesions,40 where
they express markers of anti-inflammatory cytokines and immuno-
modulatory molecules,41 presumably helping to resolve inflammation.
Chronic gray matter lesions are less inflammatory than their white
matter counterparts, and have an increased propensity to
remyelinate,31 which might in part be attributed to gray matter
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microglia more effectively resolving the damage. Normal-appearing
gray matter microglia highly express genes involved in type-I inter-
feron responses, suggesting that these cells may be more immune-
vigilant than their white matter counterparts.42 As type-I interferon
signaling in T cells produces anti-proliferative responses at least
in vitro,43 this raises the intriguing yet highly speculative possibility
that immune-vigilant gray matter microglia may dampen CNS-
infiltrating T cells.
Following the resolution of inflammation, the interactions
between microglia, oligodendrocytes and their precursors in white
matter lesions have been extensively studied. Microglia aid OPC
migration into white matter lesions, from which they have largely
been depleted during demyelination,44 and OPC differentiation into
remyelinating oligodendrocytes is supported by microglia with a pro-
regenerative phenotype.45 Rodent data indicate that OPC migration
and differentiation are more efficient in gray matter,46 suggesting that
gray matter microglia may also be more efficient in assisting these oli-
godendroglial responses leading to remyelination. Microglia in the MS
gray matter highly express genes involved in iron handling, perhaps
allowing them to clear iron released during demyelination, which par-
ticipates in oxidative injury,47 or to facilitate iron acquisition by oligo-
dendrocytes, which is required for myelin synthesis.42 Furthermore,
microglia may directly guide and/or modify remyelination by eliminat-
ing ectopic myelin sheaths as in development,48 revealing a novel
direct role for microglia in controlling myelination.
To summarize, gray matter microglia in MS are implicated in
inflammatory demyelination but may also aid successful remyelination
(Figure 1), and therefore make an attractive research target for thera-
peutic manipulation.
2.2 | Synapse dysfunction
The gray matter of the CNS harbors the majority of neuronal synap-
ses, where communicating neurons exchange information that flows
from the axonal presynaptic terminal of the input neuron to the post-
synaptic site on the soma, dendrites, or axon of the recipient neuron.
Therefore, proper neuronal communication depends upon optimal
synaptic function. In MS, structural and functional compromise of syn-
aptic connections between neurons has been reported in gray matter
areas and could account in part for the cognitive deficits of patients
with MS.49 Cognitive impairment may even precede the appearance
of typical MS clinical symptoms,50 suggesting that synaptic function
may be particularly vulnerable to subclinical disease activity. Synaptic
damage has also been suggested as a substrate for “silent” disease
progression, where disease-modifying treatments prevent the appear-
ance of white matter lesions but do not prevent the progressive accu-
mulation of disability.9 Synaptic compromise appears among the
earliest pathological events across neurodegenerative diseases includ-
ing Alzheimer's, Parkinson's disease and amyotrophic lateral sclerosis
(ALS), prior to neuronal demise, suggesting that diverse degenerative
stimuli converge to induce a common early pathological response in
synapses.22 In MS, findings suggestive of synaptic pathology fall into
three categories: (a) reduction in synaptic density within gray matter
regions, (b) functional disturbances of synaptic transmission, and
(c) perturbations in neurotransmitter homeostasis. There is evidence
implicating microglia in all of the above.
2.2.1 | Microglial involvement in synaptic
pathology
Microglia are prime suspects as effectors of MS-associated synaptic
loss, as they eliminate synaptic connections during developmental
circuit refinement to ensure proper brain connectivity,51 and aber-
rant reactivation of developmental pruning mechanisms may contrib-
ute to degeneration-associated synaptic loss.52 In MS, there is
evidence of microglial engulfment and lysosomal digestion of synap-
tic components in postmortem hippocampus,53 thalamus,54 and cer-
ebellar gray matter.55 In EAE, synaptic components are found within
microglia with a degeneration-associated phenotype before exten-
sive pathology,54 whereas in MS cortex in the absence of overt
inflammation, microglia with a rod-like morphology have been
suggested to execute synaptic stripping.56 Inhibitory synapses are
selectively reduced, compared with excitatory, in MS motor cortex20
and hippocampus,57 suggesting that they are especially vulnerable.
As synaptic components are found within MS hippocampal
microglia,57 this suggests a role for microglia in this excitatory/
inhibitory imbalance. Complement opsonization of target synapses
may facilitate their recognition by microglia,51 and increased comple-
ment deposition has been observed at hippocampal synapses in
MS.57 Notably, inhibition of synaptic complement tagging prevents
their microglial engulfment and rescues functional deficits not only
in EAE54 but also in a mouse model of Alzheimer's disease with com-
parable synaptic pathology.52 Changes in microglial phagocytosis
may also affect other structures, as for example, in MS white matter,
“do not-eat-me” signals that restrict microglial phagocytosis58 show
reduced expression.59
Microglia may also contribute to the functional compromise of
synapses in MS independent of their loss.60 In vivo in MS patients,
positron emission tomography (PET) has confirmed the presence of
activated microglia in the hippocampus61 and thalamus,62 and
proinflammatory microglial cytokines impair synaptic transmission in
the hippocampus of EAE mice.63 In cerebrospinal fluid (CSF) isolated
from MS patients high concentrations of IL-1β were capable of alter-
ing synaptic excitability in ex vivo rodent brain slices,64 and incubation
of healthy rodent brain slices with pre-activated microglia was suffi-
cient to cause synaptic functional changes.65 In EAE-affected mouse
hippocampus, microglia increase their production of reactive oxygen
species (ROS), leading to oxidative stress and impairment and/or loss
of synaptic function.66
Finally, microglia-derived proinflammatory mediators may impair
synaptic transmission by perturbing neurotransmitter homeostasis. In
postmortem MS cortex, focal reduction of transporters that maintain
physiological synaptic glutamate levels is observed in areas of micro-
glial activation.67 In EAE, IL-1β, TNF-α and ROS produced by activated
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F IGURE 1 Model of how microglia
may be involved in gray matter
demyelination and remyelination. As yet
unidentified soluble mediators diffuse
from meningeal and perivascular
inflammatory infiltrates (consisting of T
and B lymphocytes, plasma cells, dendritic
cells, and monocyte-derived
macrophages) into the gray matter,
activating resident microglia. Possible
candidates include IFN-γ, TNF-α,
proinflammatory cytokines and
chemokines, and ROS. Activated microglia
at least in early disease may secrete
proinflammatory mediators directly
damaging myelin sheaths and the
oligodendrocytes that produce and
maintain them, thus initiating
demyelination. Gray matter demyelination
may also arise secondary to demyelination
in anatomically and functionally
connected white matter areas. White
matter axonal damage may also spread via
anterograde/retrograde degeneration to
the gray matter, where it may cause
microglial “priming.” Primed microglia may
secrete myelinotoxic factors and thus
participate in the initiation of
demyelination. Microglia may also exert
pro-regenerative functions supporting
gray matter remyelination by removing
myelin debris and transforming to a pro-
regenerative phenotype as in white
matter. Gray matter microglia may also
dampen CNS-infiltrating T cell responses.
Microglia may also directly guide and/or
modify remyelination by eliminating
ectopic myelin sheaths to ensure the
accuracy of remyelination. IFN, interferon;
MS, multiple sclerosis; OPC,
oligodendrocyte precursor cell; ROS,
reactive oxygen species; TNF, tumor
necrosis factor
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microglia can suppress the expression of neuronal and astrocytic glu-
tamate transporters causing synaptic glutamate accumulation68 and
contributing to excitotoxicity, as discussed below.
2.2.2 | Microglia protect synaptic health
Although the removal of synapses or muting of their function may
appear initially destructive, it may serve a compensatory purpose,
aiming to protect surviving synapses, maintain network accuracy and
restore circuit function. Injured neurons may instruct microglia to
clear damaged synapses so that only healthy synapses remain in cir-
cuits.69 In acute EAE, synaptic sites express apoptotic signals prior to
neuronal loss and preceding their microglial removal.65 During cortical
inflammatory demyelination, microglial phagocytosis of synaptic struc-
tures is preceded by localized Ca2+ accumulation in dendritic shafts
and spines, suggestive of synaptic dysfunction.70 Microglial elimina-
tion of compromised synapses may also protect surrounding surviving
synapses from the leakage of toxic amounts of glutamate and from
the spread of oxidative stress.71 The engulfment of apoptotic synaptic
material may also transform microglia to an anti-inflammatory pheno-
type, as has been reported for macrophages in vitro, potentially damp-
ening inflammation and aiding regeneration.72
Excitatory synapse removal by microglia may also dampen neuronal
activity73 at a time of circuit vulnerability. In EAE, motor function recovery
is associated with reversible microglial displacement of synaptic contacts
during acute disease, when the risk of excitotoxicity is high, followed by
rapid re-apposition of pre- and post-synaptic elements during remission.74
Additionally, upon inflammatory stimulation, microglial ROS can reduce the
strength of excitatory synaptic transmission,75 suggesting that MS neu-
roinflammation may induce a similar microglial response to weaken synap-
tic excitability and protect network hyperactivation. Furthermore,
microglia-mediated dampening of energy-consuming synaptic transmission
may help neurons channel their resources toward survival and recovery.
A perhaps initially counter-intuitive mechanism of microglial
neuroprotection involves the temporary uncoupling of the pre- and
post-synaptic components of inhibitory synapses,76 with microglial
processes closely apposing intact neuronal somata and dendrites seen
in MS cortical lesions.18 However, at least in mice, this can mediate
neuroprotection by enhancing the activation of N-methyl-D-aspartate
glutamate receptors and the transcription of pro-survival genes in
neurons.77 Microglia also guide the activity-dependent switching of
post-synaptic structures between neighboring presynaptic inputs,78
which if it also occurred in MS may also relocate post-synapses from
compromised to nearby healthy presynaptic structures.
Finally, microglia may also aid synaptic regeneration. Microglia
are indispensable for synapse formation and maturation during CNS
plasticity, as they induce structural formation of post-synaptic
structures,79 secrete synaptotrophic factors including brain-derived
neurotrophic factor (BDNF),80 and modulate the perisynaptic extracel-
lular matrix.81 Perhaps following MS synaptic damage, microglia may
recapitulate these mechanisms for regeneration of compromised syn-
apses and support their functional maturation.
To summarize, gray matter microglia are implicated in MS-
associated synaptic pathology, by directly eliminating synaptic
connections and altering synaptic function through releasing inflam-
matory mediators. However, synaptic elimination by microglia, in at
least preclinical models, may also exert protective or restorative
effects. Further research is required to investigate whether gray
matter microglia may modulate synaptic function to impart
neuroprotection in MS (Figure 2).
2.3 | Neurodegeneration
Neurodegeneration is the progressive structural and functional com-
promise of neuronal somata, axons and dendrites, resulting in neuro-
nal death and irreversible neurological dysfunction in patients with
long-standing MS.2 Pathological findings of neurodegeneration in MS
gray matter include axonal swellings, dendritic and axonal transections
and neuronal apoptosis.18 Neurodegenerative mechanisms may be at
work from the earliest stages of MS, even sometimes when neurologi-
cal symptoms are not yet accompanied by radiological evidence
supporting an MS diagnosis.19 Recently, evidence for an MS prodrome
has emerged, uncoupling the biological from the clinical onset of the
disease, with increased serum levels of an axonal marker of degenera-
tion appearing years before symptom onset.82
The MS inflammatory milieu may drive neurodegeneration, via
neurotoxic molecules, including cytokines, ROS and glutamate pro-
duced by immune cells. ROS can induce cell death via oxidation of cel-
lular components and mitochondrial damage, causing energy
deficiency and activation of apoptotic and necrotic cascades.83 Excess
extracellular glutamate can cause neurodegeneration through
excitotoxic mechanisms, during which sustained neuronal
hyperexcitation precipitates neurotoxicity.21 However, the relative
inefficiency of immunomodulatory drugs in halting neu-
rodegeneration, and as in chronic MS neurodegeneration proceeds
behind an intact BBB, suggest that neurodegeneration may be in part
uncoupled from peripheral immune mechanisms. CNS-resident
microglia may be prime effectors of degenerative damage and are fre-
quently found around areas of such damage.
2.3.1 | Microglia participate in neurodegeneration
Microglia with a phagocytic phenotype are found in close apposition
to neuronal perikarya in areas of neuronal loss in cortex,33 and PET in
MS patients has revealed a correlation between higher cortical micro-
glial load, cortical atrophy and reduced cognitive performance.84
Microglia expressing glutamate- and ROS-synthesizing enzymes are
found around dystrophic axons and neurons containing oxidized phos-
pholipids in cortical MS lesions,85,86 and microglia-derived ROS can
lead to degeneration even of non-demyelinated axons.87 Recent
transcriptomic analysis has confirmed oxidative stress and mitochon-
drial demise within highly vulnerable neurons in upper layers of the
demyelinated cortex.88
6 MICROGLIA IN MS GRAY MATTER
Neurodegenerative pathology is comparable between MS gray
matter, Alzheimer's and ALS, and this is reflected in elements of a
degeneration-associated microglial signature being shared, at least at
the transcript level, across these conditions. This signature is charac-
terized by upregulation of proinflammatory transcripts, including
Clec7a, Gpnmb, Spp1,89,42,90 some (but not all) of which have been
F IGURE 2 Model of how microglia
may contribute to synaptic pathology but
also protect and restore synaptic health.
In MS gray matter lesions, synaptic
structures are opsonized with
complement components including C1q,
which allows their microglial recognition
via CR3, followed by their phagocytic
elimination and lysosomal digestion within
microglia. The loss of “do not-eat-me”
signals, including CD47, from synaptic
sites facilitates their microglial elimination.
Activated microglia secrete
proinflammatory cytokines including IL-1β
and ROS, which impair synaptic
transmission, suppressing the expression
of glutamate reuptake transporters on
neurons and astrocytes, leading to
glutamate accumulation in the synaptic
cleft and downstream excitotoxic synaptic
damage. However, elimination of
synapses following their externalization of
apoptotic signals like phosphatidylserine
may be beneficial, preventing leakage of
toxic amounts of glutamate and ROS to
neighboring healthy synapses, while also
maintaining network accuracy via the
prompt removal of compromised
dysfunctional synapses. Excitatory
synapse displacement by microglial
processes may also dampen neuronal
activity, preventing hyperexcitation, and
subsequent excitotoxicity. Microglial
displacement of inhibitory synapses may
enhance synaptic NMDAR activation and
downstream transcription of pro-survival
genes, imparting neuroprotection.
Microglia with a pro-regenerative
phenotype may also promote synaptic
regeneration and support their functional
maturation via secreted synaptotrophic
factors including BDNF. BDNF, brain-
derived neurotrophic factor; CD, cluster
of differentiation; CR, complement
receptor; IL, interleukin; MS, multiple
sclerosis; NMDAR, N-methyl-D-aspartate
receptor; ROS, reactive oxygen species;
TNF, tumor necrosis factor
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confirmed also at the protein level.54 Microglial phagocytosis of apo-
ptotic neurons induces this disease-associated phenotype in mouse,89
which is consistent with the hypothesis that neuronal injury from
demyelination may precipitate self-sustaining neurodegenerative
responses from CNS-resident cells.7 Vulnerable neurons in the MS
cortex upregulate transcripts for self-antigen presentation,88 perhaps
also making them targets for elimination by microglia. The reported
association between thalamic microglial activation and cortical atro-
phy in MS patients on PET84 further suggests a link between microglia
and the spread of neurodegenerative pathology along neuronal
connections.
Microglia do not act in isolation but communicate with other glia
including astrocytes, and dysfunctional microglia-astrocyte crosstalk
may contribute to MS neurodegeneration. Microglial inflammatory
mediators, including TNF-α and IL-1α, can transform astrocytes into a
neurotoxic phenotype, abundant in white matter MS lesions closely
associated to activated microglia,91 and this phenotype of astrocyte
was also identified by transcriptomic analysis of MS gray matter as
well as white.92 In EAE, inhibition of the microglial inflammasome
pathway prevented neurotoxic conversion of astrocytes, and rescued
hippocampal neuropathology and related cognitive deficits,93 empha-
sizing the importance of this crosstalk. The role of astrocytes in MS
has been comprehensively reviewed very recently94 and will not be
covered further here.
2.3.2 | Microglia mediate neuroprotection
However, microglia also act to protect the host from insult, responding
to danger signals to eliminate them and restore homeostasis. Prompt
removal of irreversibly damaged neurons may preserve network func-
tion and prevent damage to neighboring healthy tissue. Description of
these effects in white or gray matter separately is lacking in human or
mouse, but following cuprizone-induced demyelination, which affects
both gray and white matter, inhibition of microglial phagocytosis of
damaged axons generally exacerbates axonal pathology, prolongs neu-
roinflammation and impairs remyelination,95 whereas global enhance-
ment of microglial phagocytosis reduces axonal damage in spinal cord
EAE.96 In vitro, microglial phagocytosis of apoptotic neurons before
they lose their membrane integrity prevents release of proinflammatory
cell death products,71 and neuronal antigenic debris. This may be of
importance in MS, as neuronal antigens such as TAG-1 may provoke a
secondary autoimmune attack.97 Microglia also phagocytose viable but
stressed neurons, following downregulation of their “do not-eat-me”
signals.98
The degeneration-associated microglial transcriptomic signature
described in mouse models of several neurodegenerative diseases89
has not been dissected into responses of microglia from gray and
white matter. The signature includes genes that overlap with both
classical M1-proinflammatory and M2-proregenerative markers,89
suggesting that microglia in these models may play both roles. In
response to experimental stroke, microglia promote neurogenesis,
neural stem cell proliferation and differentiation,99 and this maybe
similar at least in chronic MS white matter lesions, as increased num-
bers of immature neurons are associated with hypertrophic
microglia.100 Furthermore, microglia may support axonal regeneration
during compensatory network reorganization in MS, such as by guid-
ing axonal pathfinding—similar to during development101—as they
associate with sprouting axonal spheroids in MS tissue.102 Further-
more, in human postmortem ischemic cortex, neuronal survival is
associated with increased coverage of neuronal somata by
microglia,103 suggesting physical protection. In addition, in cortical
mouse slices microglia enwrap artificially stimulated hyperactive
axons, halting the spread of hyperactivity toward the soma and
preventing excitotoxic neuronal death.104 However, we recognize that
these putative mechanisms by which gray matter microglia may aid
neuroprotection in MS are as yet unproven.
To summarize, microglia in MS gray matter participate in neuro-
nal, axonal, and dendritic damage that drive neurodegenerative
pathology. However, evidence now suggests that microglia in MS
(generally, but including those in gray matter) also may protect neuro-
nal health, support proper network function, and participate in regen-
erative efforts, and we have speculated on mechanisms by which they
do this (Figure 3).
3 | FUTURE DIRECTIONS TO
UNDERSTAND THE ROLE OF GRAY MATTER
MICROGLIA IN MS
3.1 | Dissecting the roles of different myeloid cells
and their interactions with immune cells
The increasingly appreciated heterogeneity of microglial responses to
disease is opening up new therapeutic directions but it also presents
important challenges. Novel mouse transgenic lines now allow precise
tracking and manipulation of microglia105,106 and other CNS myeloid
cells6 with high specificity, and these will help us to understand both
microglia-specific responses in the gray (and white) matter, and their
interactions with CNS border-associated macrophages and peripheral
monocyte-derived macrophages, which are of great importance in MS
where CNS communication with the periphery remains poorly under-
stood. Microglial interactions with adaptive immune cells, including T
cells, while paramount to MS pathogenesis, are also necessary in
maintaining microglial homeostasis and their interruption may lead to
microglial dysfunction.107 This raises important concerns in MS
research, where adaptive immune cells are suppressed/eliminated by
disease-modifying treatments, which may negatively impact microglial
function, and raises some urgency to understand this better.
3.2 | Heterogeneity of human myeloid cells in MS
gray vs white matter
Recent technical advances in single-cell/nuclei methods including RNA
sequencing90 and mass cytometry108 allow unbiased, high-throughput
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characterization of spatial and temporal heterogeneity of microglia in
homeostasis and disease. Profiling microglia describes the diverse
responses of these cells, but also gives us information about the
context, environmental cues and pathways that elicit these responses,
in health and disease. Regional variation in microglial transcriptomes
has been described in mouse109 and human,90,108 but a comprehensive
F IGURE 3 Model of how microglia
may participate in neurodegeneration and
neuroprotection. In MS white matter, a
degeneration-associated microglial
signature has been identified, induced by
apoptotic neuron digestion, which
includes downregulation of homeostatic
and upregulation of proinflammatory
genes. This degeneration-associated
signature awaits validation in the gray
matter—but already validated transcripts
are underlined. These microglia may
upregulate phagocytic receptor
expression, which together with the
upregulation of transcripts for self-antigen
presentation by neurons, including HLA
molecules, may lead to unrestricted
neuronal elimination. Microglia
overexpressing glutamate- and ROS-
synthesizing enzymes associate with
dystrophic neurons containing oxidized
phospholipids and damaged mitochondria.
Astrocytes with a neurotoxic reactive
phenotype abound in MS gray matter
lesions and can be induced by
proinflammatory molecules released by
activated microglia. However, the
degeneration-associated microglial
signature includes genes that overlap with
a pro-regenerative phenotype, suggesting
a potential beneficial role. Microglia may
eliminate stressed neurons, reducing the
release of harmful stress products and the
accumulation of immunogenic neuronal
debris, thus protecting nearby healthy
neurons. Microglia may also support
immature neurons/neurogenesis and
axonal regeneration in MS lesions, similar
to their developmental role, and may
physically enwrap axons to shield them
from an excitotoxic environment and
prevent the spread of hyperactivity. HLA,
human leukocyte antigen; IL, interleukin;
MS, multiple sclerosis; ROS, reactive
oxygen species; TNF, tumor necrosis
factor
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white-gray matter comparison is lacking at the single-cell level. In
human MS and mouse models, single-cell microglial profiling has mainly
been performed in white matter,110 or using mixed gray-white matter
tissue,90 which so far has hindered the identification and characteriza-
tion of microglial populations specific to pathological gray matter.
Future research in this area will help uncover differences in identity
and function of gray matter microglia and dissect their roles in MS
destructive and reparative processes. Novel technologies, such as
CITE-seq that allows simultaneous readouts at the RNA and protein
level,111 ATAC-seq that informs on chromatin accessibility and thus on
regulatory mechanisms guiding microglial identity, and spatial trans-
criptomic methods that preserve information on the spatial relationship
between cells,112 will be of critical significance. Identifying gray matter-
specific homeostatic and pathological microglial clusters will pave the
way to specifically targeting these populations to restore homeostasis
and enhance regeneration.
3.3 | Human stem cell-derived preclinical models
to study microglia in MS
A key outstanding issue in MS research (as with other diseases) is the
human translatability of findings in animal models. Although murine
and human microglia share a core expression profile and display com-
parable responses to demyelinating pathology,90 human microglia dis-
play greater heterogeneity and a more immune-vigilant signature in
homeostasis.113 Of relevance to MS, human microglia are enriched for
gene transcripts involved in crosstalk with the adaptive immune
system,114 but also in DNA repair/cell longevity and anti-
inflammatory pathways.113 Cross-species divergence is potentiated
with aging, with reduced expression of genes involved in sensing the
microenvironment, cell motility and migration in human but not in
mouse microglia.114 This divergence raises important concerns for
research in neurodegeneration and other diseases of aging, suggesting
that human-specific pathologies may not be recapitulated in com-
monly used models.
The differentiation of microglia from human induced pluripotent
stem cells (iPSCs) has opened new research opportunities to elucidate
human-specific physiology and pathology.115,116 iPSC-derived
microglia-like cells are amenable to genetic manipulations, enabling
functional studies of newly identified human genes of interest,
including those lacking murine orthologues. Co-culture with neurons
and the addition of soluble factors found in CNS milieu direct
iPSC-derived microglia toward a homeostatic state resembling CNS-
resident cells.117 Furthermore, iPSC-derived microglia can be incorpo-
rated into 3D brain organoids, where they interact with neurons,
astro- and oligodendroglia, and respond to challenge similar to CNS-
resident microglia.117 Brain region-specific organoids may recapitulate
aspects of the CNS region-specific microenvironment and thus help
shed light on context-dependent cues that shape microglial identity.
Studying microglia derived from iPSCs from MS patients may help elu-
cidate microglia-intrinsic and -extrinsic contributions to MS pathology,
as has been described for Alzheimer's disease,118 and perhaps explore
some rudimentary gene-environment interactions in a reductionist
context.
However, in in vitro models, iPSC-derived microglia are removed
from their natural habitat and thus their homeostatic signature is
altered. The generation of chimeric animal models, with transplanted
iPSC-derived microglia-like cells may provide an invaluable boost in
translational microglial research,119,120 by allowing the study and
manipulation of human microglia inside a physiological or pathological
environment, albeit a rodent one. Already it is known that human
iPSC-derived microglia retain their identity upon transplantation in
the murine brain,121 but findings need to be interpreted with caution,
as the host organism immunodeficiency required to accept the xeno-
transplantation changes the CNS immunological environment, which
may confound results. Furthermore, transplanted iPSC-derived
microglia-like cells may be distinct from true CNS-resident microglia,
due to differences in cell origin and environment122; this may con-
found research but also offer therapeutic advantages if their pheno-
type is advantageous.123 Another exciting opportunity arises with
direct reprogramming from adult cells, bypassing pluripotency, which
may conserve transcriptomic signatures of age124 and may allow the
modeling of later-life human microglial responses within the limited
lifespan of a laboratory rodent. Once the “signature” of gray matter
microglia is established, acknowledging that these may also be heter-
ogenous, then it may be possible to target iPSC differentiation into
specific microglial subtypes, followed by xenotransplantation in
rodent brains under physiological and pathological conditions to dis-
cover their functions and identify microglial populations with thera-
peutic potential.
However, therapeutic approaches targeting microglia in MS will
need to be sophisticated due to their regional and temporal pheno-
typic and functional heterogeneity. Even the “disease-associated”
microglial phenotype, which seems generic to several diseases at least
in mice, when crudely targeted, may prevent beneficial microglial acti-
vation alongside the suppression of their harmful effects,125 especially
in a chronic disease such as MS, where different stages of the disease
elicit different—and perhaps opposite—microglial responses, and iden-
tifying the optimal timing for possible intervention seems paramount.
In MS, lesions across the CNS are not synchronized in their stage of
pathology, further complicating matters. The importance of optimal
timing for harnessing microglia-mediated neuroprotection was
recently demonstrated in a brain injury model, where microglial
repopulation stimulated neuroprotective pathways and improved
functional outcomes only during the acute injury phase.126 If we can
understand the type and timing of optimal microglial therapeutic
targeting, then nanotechnological approaches may help to selectively
target harmful microglial types in areas of pathology while non-
affected regions are spared. The discovery of easily accessible bio-
markers of microglial phenotypes may also eventually allow real-time
monitoring of treatment effects in the living human brain using tech-
niques such as PET.62 Already in liver cirrhosis, the safety and tolera-
bility of autologous macrophage infusion following their in vitro
polarization to an advantageous pro-regenerative phenotype have
been demonstrated in a phase I clinical trial.127 This provides an
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exciting proof of concept for the feasibility of therapeutic neuro-
protective microglial replacement in MS patients.
4 | CONCLUSION
MS gray matter microglia contribute to demyelination, synaptic and
neuronal injury but are also implicated in inflammation resolution, syn-
aptic remodeling, neuroprotection, and regeneration. Their highly
dynamic nature allows microglia to change their gene expression on
demand, so that there may be multiple different functional states to
perform specific tasks in response to specific environmental cues. The
ongoing advances in omics technologies are furthering our under-
standing of this spectrum of microglial states in homeostasis and dis-
ease. However, the conditions that guide microglia toward
detrimental or beneficial phenotypes remain poorly understood in MS
gray matter. Therefore, the challenge for the future lies in deciphering
the context-specific responses of microglia and using that knowledge
to harness their beneficial properties while suppressing their injurious
reactions.
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